The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma.
The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Diplomat announced it has acquired MedPro Rx, a specialty pharmacy focused on specialty infusion therapies including hemophilia and immune globulin.
Sun Life Assurance Company of Canada entered into a strategic business relationship with McKesson Canada to launch the Sun Life Preferred Pharmacy Network.
Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.
Diplomat on Saturday hosted a ‘Keep Kids Safe and Healthy’ event at the specialty pharmacy's retail store.
Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business.
Shire announced that the company requested and has received a revised proposal from AbbVie that would value a proposed merger deal at $53 billion.
Novo Nordisk on Monday announced that the Food and Drug Administration approved the company's NovoSeven RT (coagulation factor VIIa [recombinant]).
The Food and Drug Administration on Thursday announced approval for Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma.